LifeMD (LFMD) Stock Forecast & Price Target

LifeMD is supported by a structurally attractive telehealth model that combines nationwide pharmacy access, a wholly owned commercial pharmacy, a fully integrated patient care center, direct-to-patient marketing, and AI-enabled clinical and operational technologies, which should help it capture demand in a market where consumers face long wait times and provider shortages. The core growth engine remains weight management, where approximately 95% of new patients initiate with branded GLP-1 therapies, weight management subscribers reached approximately 108,000 at end-2Q26, and total active subscribers grew 20% year over year to approximately 356,000, while the shift from roughly 25% to approximately 85% multi-month package adoption after the pricing change should improve retention, lifetime value, and revenue visibility. Although 2Q26 revenue of $47.3M and adjusted EBITDA of ($3.5M) came in below expectations and full-year 2026 guidance was reduced to $205.5M-$212.5M revenue and ($6M)-$0M adjusted EBITDA, the company had $25.1M in cash and no debt at the end of June 2026, and the ongoing investments in branded GLP-1 transition, insurance coverage, Medicare, and new product collaborations could support re-accelerating growth over time.

LifeMD is facing a negative fundamental setup because 2Q26 revenue of $47.3M declined 4% YoY and missed expectations, while FY2026 revenue guidance was cut to $205.5M-$212.5M from $220M-$230M as the company acknowledged it underestimated the near-term profitability impact of pricing changes and the shift toward branded GLP-1 therapies. Although total active subscribers rose 20% YoY to approximately 356,000 and weight management subscribers reached about 108,000, adjusted EBITDA is still guided to only break even to ($6M) for FY2026, with 3Q26 expected at just ($1M) to $2M, underscoring limited earnings power despite growing volume. The accelerated women’s health opportunity and July 2026 XYOSTED launch add optionality, but the revised outlook already includes $2M-$3M of launch costs and the business remains highly exposed to a competitive telehealth market, making the path to durable margin expansion and consistent profitability uncertain.